B. LYNNE PARSHALL, J.D.
Director, Chief Operating Officer
Ms. Parshall has served as a Director of Isis since September 2000. She has been our Chief Operating
Officer since December 2007 and previously served as our Chief Financial Officer from June 1994 to December
2012. She also served as our Corporate Secretary through 2014 and has served in various executive roles since
November 1991. Prior to joining Isis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Isis, where
she was a partner from 1986 to 1991. Ms. Parshall is a member of theAmerican, California and San Diego bar
associations.
C. FRANKBENNETT, Ph.D.
Senior Vice President, Antisense Research
Dr. Bennett was promoted to Senior Vice President, Antisense Research in January 2006. From June 1995 to
January 2006, Dr. Bennett served as our Vice President, Research. FromMarch 1993 to June 1995, he was
Director, Molecular Pharmacology, and fromMay 1992 toMarch 1993, he was anAssociate Director in our
Molecular and Cellular Biology department. Prior to joining Isis in 1989, Dr. Bennett was employed by
SmithKline and French Laboratories in various research positions. He is an external member of the Scientific
Advisory Board of Experimental Therapeutics Center in Singapore.
SARAHBOYCE
Chief Business Officer
Ms. Boyce joined Isis in January 2015 as our Chief Business Officer. Prior to joining Isis, Ms. Boyce was
Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. from 2012 to
2014. She was Vice President, Global Head Nephrology Therapeutics Area of Alexion Pharmaceuticals from
2010 to 2011. She held various positions at Novartis GroupAG, including Vice President, Global ProgramHead,
Pediatric and Specialty from 2000 to 2010. Prior to that, Ms. Boyce held positions at Bayer Pharmaceuticals and
Roche.
RICHARD S. GEARY, Ph.D.
Senior Vice President, Development
Dr. Geary was promoted to Senior Vice President, Development inAugust 2008. FromAugust 2003 to
August 2008, Dr. Geary served as our Vice President, Preclinical Development. FromNovember 1995 toAugust
2003, he held various positions within the Preclinical Development department. Prior to joining Isis in 1995, Dr.
Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics
group in theApplied Chemistry Department at Southwest Research Institute.
ELIZABETHL. HOUGEN
Senior Vice President, Finance and Chief Financial Officer
Ms. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013.
From January 2007 to December 2012, Ms. Hougen served as our Vice President, Finance and Chief Accounting
Officer and fromMay 2000 to January 2007, she served as our Vice President, Finance. Prior to joining Isis in
2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc.,
a public biotechnology company.
BRETT P. MONIA, Ph.D.
Senior Vice President, Drug Discovery and Corporate Development
Dr. Monia was promoted to Senior Vice President, Drug Discovery and Corporate Development in January
2012. FromFebruary 2009 to January 2012, Dr. Monia served as our Vice President, Drug Discovery and
Corporate Development and fromOctober 2000 to February 2009, he served as our Vice President, Preclinical
Drug Discovery. FromOctober 1989 to October 2000 he held various positions within our Molecular
Pharmacology department.
53
